Literature DB >> 26095926

The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer.

Gunnar Wichmann1,2, Maciej Rosolowski2,3, Knut Krohn4, Markus Kreuz3, Andreas Boehm1, Anett Reiche1, Ulrike Scharrer1,2, Dirk Halama5, Julia Bertolini6, Ulrike Bauer6, Dana Holzinger7, Michael Pawlita7, Jochen Hess8,9, Christoph Engel2,3, Dirk Hasenclever3, Markus Scholz2,3, Peter Ahnert2,3, Holger Kirsten2,3, Alexander Hemprich5, Christian Wittekind6, Olf Herbarth2,10, Friedemann Horn2,11, Andreas Dietz1,2, Markus Loeffler2,3.   

Abstract

Stratification of head and neck squamous cell carcinomas (HNSCC) based on HPV16 DNA and RNA status, gene expression patterns, and mutated candidate genes may facilitate patient treatment decision. We characterize head and neck squamous cell carcinomas (HNSCC) with different HPV16 DNA and RNA (E6*I) status from 290 consecutively recruited patients by gene expression profiling and targeted sequencing of 50 genes. We show that tumors with transcriptionally inactive HPV16 (DNA+ RNA-) are similar to HPV-negative (DNA-) tumors regarding gene expression and frequency of TP53 mutations (47%, 8/17 and 43%, 72/167, respectively). We also find that an immune response-related gene expression cluster is associated with lymph node metastasis, independent of HPV16 status and that disruptive TP53 mutations are associated with lymph node metastasis in HPV16 DNA- tumors. We validate each of these associations in another large data set. Four gene expression clusters which we identify differ moderately but significantly in overall survival. Our findings underscore the importance of measuring the HPV16 RNA (E6*I) and TP53-mutation status for patient stratification and identify associations of an immune response-related gene expression cluster and TP53 mutations with lymph node metastasis in HNSCC.
© 2015 UICC.

Entities:  

Keywords:  APC; TP53; consensus clustering; gene expression; head and neck squamous cell carcinoma; human papillomavirus; neck metastasis

Mesh:

Substances:

Year:  2015        PMID: 26095926     DOI: 10.1002/ijc.29649

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  67 in total

Review 1.  [Gene expression analyses and their possible clinical benefit in head and neck cancer].

Authors:  A Dietz; M Loeffler; M Rosolowski; M Kreuz; F Lordick; M Knödler; C Mozet; G Wichmann
Journal:  HNO       Date:  2015-11       Impact factor: 1.284

Review 2.  [Human papillomavirus and squamous cell cancer of the head and neck region : Prognostic, therapeutic and prophylactic implications].

Authors:  M Reuschenbach; S Wagner; N Würdemann; S J Sharma; E-S Prigge; M Sauer; A Wittig; C Wittekindt; M von Knebel Doeberitz; J P Klussmann
Journal:  HNO       Date:  2016-07       Impact factor: 1.284

3.  Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma.

Authors:  Bangrong Cao; Qifeng Wang; Huan Zhang; Guiquan Zhu; Jinyi Lang
Journal:  Oncoimmunology       Date:  2017-11-06       Impact factor: 8.110

Review 4.  [Preclinical models to establish innovative therapy strategies : Ex‑vivo assessment of head and neck tumor chemo- and immune responses].

Authors:  G Wichmann; A Dietz
Journal:  HNO       Date:  2016-07       Impact factor: 1.284

Review 5.  The molecular landscape of head and neck cancer.

Authors:  C René Leemans; Peter J F Snijders; Ruud H Brakenhoff
Journal:  Nat Rev Cancer       Date:  2018-03-02       Impact factor: 60.716

Review 6.  Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application?

Authors:  Luca Tonella; Marco Giannoccaro; Salvatore Alfieri; Silvana Canevari; Loris De Cecco
Journal:  Curr Treat Options Oncol       Date:  2017-05

7.  HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers.

Authors:  Lada A Koneva; Yanxiao Zhang; Shama Virani; Pelle B Hall; Jonathan B McHugh; Douglas B Chepeha; Gregory T Wolf; Thomas E Carey; Laura S Rozek; Maureen A Sartor
Journal:  Mol Cancer Res       Date:  2017-09-19       Impact factor: 5.852

8.  AKR1C3 is a biomarker and druggable target for oropharyngeal tumors.

Authors:  Caterina Peraldo-Neia; Paola Ostano; Maurizia Mello-Grand; Francesca Guana; Ilaria Gregnanin; Donatella Boschi; Simonetta Oliaro-Bosso; Agnese Chiara Pippione; Andrea Carenzo; Loris De Cecco; Stefano Cavalieri; Arianna Micali; Federica Perrone; Gianluca Averono; Paolo Bagnasacco; Riccardo Dosdegani; Laura Masini; Marco Krengli; Paolo Aluffi-Valletti; Guido Valente; Giovanna Chiorino
Journal:  Cell Oncol (Dordr)       Date:  2020-11-19       Impact factor: 6.730

9.  Subtypes of HPV-Positive Head and Neck Cancers Are Associated with HPV Characteristics, Copy Number Alterations, PIK3CA Mutation, and Pathway Signatures.

Authors:  Yanxiao Zhang; Lada A Koneva; Shama Virani; Anna E Arthur; Alisha Virani; Pelle B Hall; Charles D Warden; Thomas E Carey; Douglas B Chepeha; Mark E Prince; Jonathan B McHugh; Gregory T Wolf; Laura S Rozek; Maureen A Sartor
Journal:  Clin Cancer Res       Date:  2016-04-18       Impact factor: 12.531

Review 10.  Highlights from the Second International Symposium on HPV infection in head and neck cancer.

Authors:  Susanne Wiegand; G Wichmann; W Golusinski; C R Leemans; J P Klussmann; A Dietz
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-03-27       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.